General description
A cell-permeable triaminotriazine ROCK inhibitor (IC50 = 6 nM in a cell-free ROCK1 kinase assay) that affects 24 other commonly studied non-ROCK kinases only at much higher concentrations (IC50 >2 µM) and effectively blocks MCP-1-induced THP-1 cell migration (IC50 = 30 nM) in vitro. Subcutaneous injection (3-10 mg/kg) of ROCK Inhibitor VII and oral dosing (30 mg/kg) of Y-27632 (Cat. Nos. 688000 & 688001) are both reported to significantly reduce arterial blood pressure in a spontaneous hypertensive rat model in vivo.
A cell-permeable triaminotriazine ROCK inhibitor (IC50 = 6 nM in a cell-free ROCK1 kinase assay) that affects 24 other commonly studied non-ROCK kinases only at much higher concentrations (IC50 >2 µM) and effectively blocks MCP-1-induced THP-1 cell migration (IC50 = 30 nM) in vitro. Subcutaneous injection (3-10 mg/kg) of ROCK Inhibitor VII and oral dosing (30 mg/kg) of Y-27632 (Cat. Nos. 688000 & 688001) are both reported to significantly reduce arterial blood pressure in a spontaneous hypertensive rat model in vivo.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Ho, K.K., et al. 2009. Bioorg. Med. Chem. Lett.19, 6027.
Packaging
Packaged under inert gas
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria: